Previsioni

Il prezzo obiettivo medio degli analisti è 51,35 € (+102,88%). La mediana è 51,35 € (+102,88%).

Acquista	18
Mantieni	8
Vendi	1

Notizie Vai al feed delle notizie

Arbitration ruling weighs on Beam Therapeutics: stock falls after loss of PM647 rights

An arbitration panel ruled in a dispute with Prime Medicine that the development rights for the experimental gene therapy PM647 fall within Prime Medicine’s licensed field, causing Beam Therapeutics to lose those rights. This also affects the competing AATD program BEAM-302 and increases competitive and patent-related uncertainty for Beam. The stock fell from its 52-week high and gave back gains, further pressured by a risk-averse market environment after geopolitical tensions that hit high-growth biotech stocks disproportionately. » Altro su de.investing.com
Beam Therapeutics plans to file an FDA approval application for BEAM-101 in 2026 and has several clinical milestones in sight

Beam Therapeutics still plans to submit the approval application for BEAM-101 to treat severe sickle cell disease in 2026. BEAM-302 is pursuing an accelerated FDA approval for alpha-1 antitrypsin deficiency, and an IND has been submitted for BEAM-304 to treat phenylketonuria. The company expects noticeable revenue growth from 2028 and holds about $1.2 billion in cash, which should secure funding through 2029. » Altro su finanzen.net
Beam Therapeutics reaches 52-week high at $36.89

Beam Therapeutics’ stock climbed to a 52-week high of $36.89 and is currently trading at $37.02 with a market capitalization of $3.63 billion. InvestingPro rates the stock as potentially overvalued versus its fair-value estimate; investors should note the high volatility, with a beta of 2.18. The FDA approved the IND application for BEAM-304 to treat phenylketonuria, Beam presented Phase 1/2 data for BEAM-302, and H.C. Wainwright confirmed a buy recommendation with an $80.00 price target; updated data on Risto-Cel will be presented at the EHA. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2013, BEAM THERAPEUTICS DL-,01 ha già distribuito 0,51 € di dividendi. L'ultimo pagamento è avvenuto a dicembre 2013.

Dati finanziari dell'azienda

Nell'ultimo trimestre, BEAM THERAPEUTICS DL-,01 ha registrato ricavi pari a 429,34K € e un utile netto di -107,49 Mln €

(EUR)	giu 2026	YoY
Ricavi	429,34K	94,02%
Utile lordo	429,34K	100,54%
Utile netto	-107,49 Mln	23,86%
EBITDA	-109,54 Mln	33,45%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	2,68 Mld €
Numero di azioni	102,88 Mln
Massimo/minimo a 52 settimane	33,02 € - 13,83 €
Dividendi	No
Beta	2,21
Rapporto P/E	-36,82
Rapporto PEG	-0,50
Rapporto P/B	2,95
Rapporto P/S	19,91

Profilo aziendale

Beam Therapeutics Inc. ist ein Biotechnologieunternehmen, das genetische Präzisionsarzneimittel für Patienten mit schweren Krankheiten in den Vereinigten Staaten entwickelt. Das Unternehmen entwickelt BEAM-101 zur Behandlung der Sichelzellkrankheit und der Beta-Thalassämie, BEAM-102 zur Behandlung der Sichelzellkrankheit und BEAM-201, eine allogene chimäre Antigenrezeptor-T-Zelle zur Behandlung der rezidivierenden/refraktären akuten lymphoblastischen T-Zell-Leukämie, sowie BEAM-301, einen auf die Leber ausgerichteten Entwicklungskandidaten für die Behandlung von Patienten mit Glykogenspeicherkrankheit Typ Ia. Darüber hinaus entwickelt das Unternehmen Therapien für Alpha-1-Antitrypsin-Mangel, Augenkrankheiten und andere Erkrankungen der Leber, der Muskeln und des zentralen Nervensystems. Das Unternehmen unterhält eine Allianz mit dem Boston Children's Hospital, ein Kooperationsabkommen mit Magenta Therapeutics, Inc. für Forschung und klinische Studien, ein Lizenzabkommen mit Sana Biotechnology, Inc. und eine Forschungskooperation mit dem Institute of Molecular and Clinical Ophthalmology Basel. Es hat auch eine Forschungskooperation mit Pfizer Inc. und Apellis Pharmaceuticals, Inc. sowie eine Kooperations- und Lizenzvereinbarung mit Verve Therapeutics, Inc. Das Unternehmen wurde im Jahr 2017 gegründet und hat seinen Sitz in Cambridge, Massachusetts.

Nome	BEAM THERAPEUTICS DL-,01
CEO	John Evans
Sede centrale	Cambridge, ma Stati Uniti
Sito web	beamtx.com
Settore	Beni di prima necessità
Industria	Prodotti alimentari
Quotazione in borsa	06/02/2020
Dipendenti	540